HCV
Conditions
Keywords
HCV
Brief summary
In this study, the investigator would conduct an ambispective cohort study to build a prediction model of HCV-related disease after DAAs.
Detailed description
The emergence of direct antiviral agents (DAAs) makes it possible to cure HCV, and the sustained virological response (SVR) rate is up to 90% after DAAs therapy. However, the acquisition of SVR does not mean the cure of HCV-related diseases, some patients still developed liver cirrhosis, liver cancer and other diseases after achived SVR by DAAs therapy.In this study the investigator would like to bulid a prediction model of HCV-related disease after DAAs by conducting an ambispective cohort study. The participants of this study would be adult patients (≥18 years old) with chronic HCV infection and have received DAA therapy, the investigator would retrospectively collected DAA therapy-related information, and follow-up all the enrolled participants every 6 months to observe their liver-related disease outcomes (composite liver outcome, including liver-related deaths, hepatocellular carcinoma, liver decompensation, and liver transplantation).
Interventions
None listed
Sponsors
Peking University People's Hospital
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* adult patients (≥18 years old) with chronic HCV infection that were HCV RNA positive; * have received DAA treatment; * would like to adhere to the follow-up
Exclusion criteria
* lack of HCV treatment information;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| incidence of composit liver-related events | through study completion, an average of 2 year | Composite liver outcomes, including liver-related deaths, hepatocellular carcinoma, liver decompensation, or liver transplantation. |
Contacts
Primary ContactHuixin Liu, Ph.D.
Outcome results
None listed